Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan

Yasuhiro Kamioka,1,2 Shota Kashiwagura,1,2 Masafumi Seki1 1Department of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai City, Miyagi, Japan; 2Division of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, JapanCorresp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kamioka Y, Kashiwagura S, Seki M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	anti-influenza agents oseltamivir laninamivir zanamivir peramivir novel coronavirus-2019 (covid-19) Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/fae75e6d7afa439990fc25aba94beb98
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fae75e6d7afa439990fc25aba94beb98
record_format	dspace
spelling	oai:doaj.org-article:fae75e6d7afa439990fc25aba94beb982021-12-02T12:39:04ZReduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan1179-1438https://doaj.org/article/fae75e6d7afa439990fc25aba94beb982020-08-01T00:00:00Zhttps://www.dovepress.com/reduced-prescription-of-baloxavir-after-suspected-prevalence-of-a-balo-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Yasuhiro Kamioka,1,2 Shota Kashiwagura,1,2 Masafumi Seki1 1Department of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai City, Miyagi, Japan; 2Division of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, JapanCorrespondence: Masafumi SekiDepartment of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-Ku, Sendai City, Miyagi 983-8612, JapanTel +81-22-259-1221Fax +81-22-290-8956Email m-seki@tohoku-mpu.ac.jpObjective: The use of baloxavir, a new anti-influenza agent, began in Japan from the 2018 to 2019 season and became the focus of attention due to its efficient viral reduction ability; therefore, we should know the prescription changes of anti-influenza agents.Methods: We analyzed the changes in the prescription of anti-influenza agents between the 2018– 19 season and the 2019– 20 season in our hospital.Results: The share of baloxavir was 15%, while the shares of oseltamivir and laninamivir were 42% and 31%, respectively in the 2018– 2019 season. However, in the 2019– 20 season, the share of baloxavir and laninamivir was reduced to 3% and 17%, respectively, in contrast to an increase in the share of oseltamivir (66%). The total prescription of anti-influenza agents for patients decreased in the 2019– 20 season (205 patients), compared with the 2018– 19 season (509 patients).Conclusion: These results suggest significant changes such as a reduction in the prescription of anti-influenza agents, especially baloxavir, likely due to the suspected prevalence of a baloxavir-resistant strain of influenza virus and the emergence of SARS-CoV-2 in Japan.Keywords: anti-influenza agents, oseltamivir, laninamivir, zanamivir, peramivir, novel coronavirus-2019, COVID-19Kamioka YKashiwagura SSeki MDove Medical Pressarticleanti-influenza agentsoseltamivirlaninamivirzanamivirperamivirnovel coronavirus-2019 (covid-19)Therapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 131-134 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-influenza agents oseltamivir laninamivir zanamivir peramivir novel coronavirus-2019 (covid-19) Therapeutics. Pharmacology RM1-950
spellingShingle	anti-influenza agents oseltamivir laninamivir zanamivir peramivir novel coronavirus-2019 (covid-19) Therapeutics. Pharmacology RM1-950 Kamioka Y Kashiwagura S Seki M Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
description	Yasuhiro Kamioka,1,2 Shota Kashiwagura,1,2 Masafumi Seki1 1Department of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai City, Miyagi, Japan; 2Division of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, JapanCorrespondence: Masafumi SekiDepartment of Infectious Diseases, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-Ku, Sendai City, Miyagi 983-8612, JapanTel +81-22-259-1221Fax +81-22-290-8956Email m-seki@tohoku-mpu.ac.jpObjective: The use of baloxavir, a new anti-influenza agent, began in Japan from the 2018 to 2019 season and became the focus of attention due to its efficient viral reduction ability; therefore, we should know the prescription changes of anti-influenza agents.Methods: We analyzed the changes in the prescription of anti-influenza agents between the 2018– 19 season and the 2019– 20 season in our hospital.Results: The share of baloxavir was 15%, while the shares of oseltamivir and laninamivir were 42% and 31%, respectively in the 2018– 2019 season. However, in the 2019– 20 season, the share of baloxavir and laninamivir was reduced to 3% and 17%, respectively, in contrast to an increase in the share of oseltamivir (66%). The total prescription of anti-influenza agents for patients decreased in the 2019– 20 season (205 patients), compared with the 2018– 19 season (509 patients).Conclusion: These results suggest significant changes such as a reduction in the prescription of anti-influenza agents, especially baloxavir, likely due to the suspected prevalence of a baloxavir-resistant strain of influenza virus and the emergence of SARS-CoV-2 in Japan.Keywords: anti-influenza agents, oseltamivir, laninamivir, zanamivir, peramivir, novel coronavirus-2019, COVID-19
format	article
author	Kamioka Y Kashiwagura S Seki M
author_facet	Kamioka Y Kashiwagura S Seki M
author_sort	Kamioka Y
title	Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
title_short	Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
title_full	Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
title_fullStr	Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
title_full_unstemmed	Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
title_sort	reduced prescription of baloxavir after suspected prevalence of a baloxavir-resistant influenza virus strain and the emergence of sars-cov-2 in a tertiary hospital in japan
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/fae75e6d7afa439990fc25aba94beb98
work_keys_str_mv	AT kamiokay reducedprescriptionofbaloxaviraftersuspectedprevalenceofabaloxavirresistantinfluenzavirusstrainandtheemergenceofsarscov2inatertiaryhospitalinjapan AT kashiwaguras reducedprescriptionofbaloxaviraftersuspectedprevalenceofabaloxavirresistantinfluenzavirusstrainandtheemergenceofsarscov2inatertiaryhospitalinjapan AT sekim reducedprescriptionofbaloxaviraftersuspectedprevalenceofabaloxavirresistantinfluenzavirusstrainandtheemergenceofsarscov2inatertiaryhospitalinjapan
_version_	1718393837859110912

Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan

Ejemplares similares